FibroGen (FGEN) Competitors $6.89 -0.03 (-0.43%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$6.85 -0.04 (-0.58%) As of 08/1/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. SKYE, MCRB, CNTB, SAVA, ZURA, COYA, CLYM, SCLX, HLVX, and ANIXShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Skye Bioscience (SKYE), Seres Therapeutics (MCRB), Connect Biopharma (CNTB), Cassava Sciences (SAVA), Zura Bio (ZURA), Coya Therapeutics (COYA), Climb Bio (CLYM), Scilex (SCLX), HilleVax (HLVX), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Skye Bioscience Seres Therapeutics Connect Biopharma Cassava Sciences Zura Bio Coya Therapeutics Climb Bio Scilex HilleVax Anixa Biosciences FibroGen (NASDAQ:FGEN) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has more risk and volatility, FGEN or SKYE? FibroGen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Do analysts rate FGEN or SKYE? FibroGen presently has a consensus price target of $250.00, suggesting a potential upside of 3,528.45%. Skye Bioscience has a consensus price target of $16.60, suggesting a potential upside of 386.80%. Given FibroGen's higher probable upside, equities research analysts clearly believe FibroGen is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of FGEN or SKYE? 72.7% of FibroGen shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 3.1% of FibroGen shares are held by company insiders. Comparatively, 4.5% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer FGEN or SKYE? In the previous week, Skye Bioscience had 3 more articles in the media than FibroGen. MarketBeat recorded 3 mentions for Skye Bioscience and 0 mentions for FibroGen. Skye Bioscience's average media sentiment score of 0.50 beat FibroGen's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Overall Sentiment FibroGen Neutral Skye Bioscience Positive Is FGEN or SKYE more profitable? Skye Bioscience has a net margin of 0.00% compared to FibroGen's net margin of -9.73%. FibroGen's return on equity of 0.00% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-9.73% N/A -24.77% Skye Bioscience N/A -53.92%-48.58% Which has higher valuation and earnings, FGEN or SKYE? Skye Bioscience has lower revenue, but higher earnings than FibroGen. Skye Bioscience is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M0.94-$47.58M-$2.50-2.76Skye BioscienceN/AN/A-$26.57M-$0.82-4.16 SummarySkye Bioscience beats FibroGen on 9 of the 15 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.97M$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-2.768.9728.6723.80Price / Sales0.94639.67422.3188.12Price / CashN/A157.7635.4557.96Price / Book-0.144.838.275.55Net Income-$47.58M$31.62M$3.24B$259.03M7 Day Performance-7.52%-5.28%-3.63%-4.56%1 Month Performance31.24%4.38%4.40%4.49%1 Year Performance-35.61%-2.49%25.97%18.05% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.3966 of 5 stars$6.89-0.4%$250.00+3,528.4%-41.4%$27.97M$29.62M-2.76570Upcoming EarningsSKYESkye Bioscience1.4543 of 5 stars$3.74-4.3%$16.60+343.9%-37.8%$115.87MN/A-4.5611Gap DownMCRBSeres Therapeutics2.9283 of 5 stars$13.24-8.9%$73.67+456.4%-44.5%$115.61MN/A-2.88330News CoverageUpcoming EarningsGap UpCNTBConnect Biopharma2.9786 of 5 stars$2.08-6.3%$7.00+236.5%+73.9%$115.57M$26.03M0.00110Short Interest ↑SAVACassava Sciences3.5719 of 5 stars$2.38+1.3%$54.50+2,189.9%-91.0%$114.98MN/A-1.5930ZURAZura Bio3.6132 of 5 stars$1.62-1.2%$14.33+784.8%-60.1%$110.77MN/A-2.313News CoveragePositive NewsCOYACoya Therapeutics1.9488 of 5 stars$6.62-0.7%$16.50+149.2%-9.6%$110.75M$3.55M-6.196CLYMClimb Bio2.3341 of 5 stars$1.60+10.3%$9.00+462.5%N/A$108.13MN/A-0.679Positive NewsHigh Trading VolumeSCLXScilex2.072 of 5 stars$15.52+29.8%$455.00+2,831.7%-74.5%$107.86M$56.59M-0.5380News CoverageGap DownHigh Trading VolumeHLVXHilleVax1.8451 of 5 stars$2.13-0.9%$2.00-6.1%+15.3%$106.80MN/A-0.9920News CoveragePositive NewsANIXAnixa Biosciences3.2883 of 5 stars$3.29+2.2%$9.00+173.6%-11.2%$105.97M$210K-8.665 Related Companies and Tools Related Companies Skye Bioscience Competitors Seres Therapeutics Competitors Connect Biopharma Competitors Cassava Sciences Competitors Zura Bio Competitors Coya Therapeutics Competitors Climb Bio Competitors Scilex Competitors HilleVax Competitors Anixa Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FGEN Stock Alerts